The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart disease — the first new treatment for the condition in over five years and the company’s first significant commercial product.
The drug, known scientifically as acoramidis, will be sold by BridgeBio under the brand name Attruby.
The FDA cleared Attruby to treat patients with the heart condition known as transthyretin amyloid cardiomyopathy, or ATTR-CM. Once thought to be a rare disease, ATTR-CM is now estimated to affect more than 400,000 people globally. The condition, which is caused either by a genetic mutation or by aging, leads patients’ livers to produce unstable proteins that misfold and clump into amyloid deposits in the heart, gradually impairing its function. Without treatment, most patients die within five years of diagnosis.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
